Dr. Ankur Varma, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 201
Licensed in Illinois since 2019, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
AR license E-16865 -
Hematology (Internal Medicine) Physician
AR license E-16865 -
Hematology & Oncology Physician
IL license 036-148500 (first issued 2019; active) -
Internal Medicine Physician
AR license E-16865
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Arkansas Medical Sciences Little Rock, AR
Medical groups
- University of Arkansas for Medical Sciences (1,175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 201
- Services billed
- 704
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 193 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 63 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 17 |
| Hospital discharge day management, more than 30 minutes | 15 | 15 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Little Rock, AR | 71 |
| Brukinsa (zanubrutinib) | 39 |
| Eliquis (apixaban) Other prescribers in Little Rock, AR | 32 |
| Potassium Chloride Other prescribers in Little Rock, AR | 30 |
| Fluconazole Other prescribers in Little Rock, AR | 30 |
| Levofloxacin Other prescribers in Little Rock, AR | 29 |
| Prochlorperazine Maleate Other prescribers in Little Rock, AR | 26 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Little Rock, AR | 20 |
| Promacta (eltrombopag olamine) | 19 |
| Dapsone | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $18,700 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie Inc. · Recruiting · NCT06428019
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.